Comparing the effectiveness of two medications for plaque psoriasis
A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region
This study is testing whether deucravacitinib or apremilast works better for adults with plaque psoriasis who are starting treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Drugs / interventions | deucravacitinib |
| Locations | 1 site (Waltham, Massachusetts) |
| Trial ID | NCT05744466 on ClinicalTrials.gov |
What this trial studies
This observational study aims to compare the effectiveness of deucravacitinib and apremilast in adults diagnosed with plaque psoriasis. Participants will be newly initiating one of these medications and will be enrolled in the CorEvitas Psoriasis Registry, allowing for real-world data collection on treatment outcomes. The study will analyze patient-reported outcomes and clinical effectiveness over time, providing insights into which medication may offer better results for patients.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with plaque psoriasis who are starting treatment with either deucravacitinib or apremilast.
Not a fit: Patients currently participating in interventional clinical trials or those who have previously received the study medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify the more effective treatment option for patients with plaque psoriasis.
How similar studies have performed: Other studies comparing treatment effectiveness in psoriasis have shown promising results, indicating that this approach is supported by previous research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have been diagnosed with plaque psoriasis by a dermatologist * Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) * Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Exclusion Criteria: * Participation (current or planned) in an interventional clinical trial (does not include observational registry or study) * Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history
Where this trial is running
Waltham, Massachusetts
- Local Institution — Waltham, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.